Pages that link to "Q39965971"

The following pages link to Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib. (Q39965971):

Displaying 35 items.

• Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum (Q24594356) (← links)
• Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks? (Q24597424) (← links)
• Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth (Q33623874) (← links)
• Novel dual Src/Abl inhibitors for hematologic and solid malignancies (Q34121339) (← links)
• STAT3 Inhibition Is a Therapeutic Strategy for ABC-like Diffuse Large B-Cell Lymphoma (Q34900634) (← links)
• Controversies in the treatment of Burkitt lymphoma in AIDS (Q36151295) (← links)
• Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia (Q36201677) (← links)
• Inhibitors of SRC kinases impair antitumor activity of anti-CD20 monoclonal antibodies. (Q36213094) (← links)
• Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma. (Q36649225) (← links)
• Antitumor effects of Dasatinib on laryngeal squamous cell carcinoma in vivo and in vitro (Q36718435) (← links)
• New developments in the pathology of malignant lymphoma: a review of the literature published from May to July 2008 (Q37268997) (← links)
• Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation (Q37576259) (← links)
• Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment (Q37706530) (← links)
• B-cell receptor pathobiology and targeting in NHL. (Q38032206) (← links)
• Signaling pathways in lymphoma: pathogenesis and therapeutic targets (Q38150876) (← links)
• Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment (Q38714409) (← links)
• Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma. (Q38819065) (← links)
• Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. (Q38959765) (← links)
• Expression and pro-survival function of phospholipase Cγ2 in diffuse large B-cell lymphoma (Q38976449) (← links)
• BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity (Q39056302) (← links)
• Antitumor activity of new pyrazolo[3,4-d]pyrimidine SRC kinase inhibitors in Burkitt lymphoma cell lines and its enhancement by WEE1 inhibition (Q39396721) (← links)
• SYK inhibition and response prediction in diffuse large B-cell lymphoma (Q39453213) (← links)
• Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib (Q39507461) (← links)
• Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals (Q39586039) (← links)
• E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia (Q42265707) (← links)
• Current Progress in EBV-Associated B-Cell Lymphomas (Q47606345) (← links)
• Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. (Q51072600) (← links)
• HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment. (Q51173647) (← links)
• Early events of B-cell receptor signaling are not essential for the proliferation and viability of AIDS-related lymphoma. (Q55050978) (← links)
• Variable Responses of MYC Translocation Positive Lymphoma Cell Lines To Different Combinations of Novel Agents: Impact of BCL2 Family Protein Expression. (Q64974176) (← links)
• Turning liabilities into opportunities: Off-target based drug repurposing in cancer (Q89651597) (← links)
• Dasatinib reverses drug resistance by downregulating MDR1 and Survivin in Burkitt lymphoma cells (Q90324805) (← links)
• New roles for B cell receptor associated kinases: when the B cell is not the target (Q91283875) (← links)
• Repurposing dasatinib for diffuse large B cell lymphoma (Q92430952) (← links)
• SOCS1: phosphorylation, dimerization and tumor suppression (Q92955391) (← links)